FIG 1.
Trial profile. Analysis in participants with PD-L1 CPS ≥ 20 was prespecified, and the trial profile for these participants has been published previously.11 Reasons that patients discontinued treatment in each subgroup are presented in the Data Supplement. CPS, combined positive score; PD-L1, programmed death ligand-1.